Evidence map›Paper›PMID 33220806›Full record

ReviewSurgical oncology clinics of North America2021

Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments.

Yoshikuni Kawaguchi, Mario De Bellis, Elena Panettieri, Gregor Duwe, Jean-Nicolas Vauthey

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Surgical oncology clinics of North America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Neoadjuvant Pelvic Radiotherapy in the Management of Rectal Cancer with Synchronous Liver Metastases: Is It Worth It?Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yoshikuni KawaguchiDepartment of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA; Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.
Mario De BellisDepartment of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Elena PanettieriDepartment of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Gregor DuweDepartment of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Jean-Nicolas VautheyDepartment of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jvauthey@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
TRAINING OF ACADEMIC SURGICAL ONCOLOGISTST32CA009599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Ashley M Holder, Jennifer A. Wargo · 1988 to 2026
$13.2M
NCI NIH HHS P30 CA016672NCI NIH HHS T32 CA009599
6 · The paper itself

Abstract

The benefit of resection of liver metastases depends on primary diseases. Neuroendocrine tumors are associated with favorable prognosis after resection of liver metastases. Gastric cancer has worse tumor biology, and resection of gastric liver metastases should be performed in selected patients. A multidisciplinary approach is well established for colorectal liver metastases (CLMs). Resection remains the only curative treatment of CLM. Chemotherapy and molecular-targeted therapy have improved survival in unresectable metastatic colorectal cancer. Understanding of the following two strategies, conversion therapy and two-stage hepatectomy, are important to make this patient group to be candidates for curative-intent surgery.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsHepatectomyHumansNeoplasm StagingPrognosisChemotherapyColorectal liver metastasisConversion therapyGastric liver metastasisMolecular-targeted therapyNeuroendocrine liver metastasisResectionTwo-stage hepatectomy

Identifiers

PMID33220806
PMCPMC7709757
OpenAlexW3107978352

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.